For decades, Medicare has been legally prohibited from covering weight-loss medications — a statutory relic of an era when obesity was framed as a lifestyle choice rather than a chronic clinical condition. The Trump administration's proposed BALANCE pilot program seeks to bypass this restriction, testing the hypothesis that broad access to GLP-1 receptor agonists could improve health outcomes and potentially lower long-term costs for the federal government. But the initiative now faces a structural problem: the private insurers it needs as partners are not convinced the math works in their favor.
The program relies on a negotiated deal with pharmaceutical giants Eli Lilly and Novo Nordisk. Under the terms, the manufacturers would sell their popular obesity treatments to Medicare and Medicaid for $245 a month, with seniors' out-of-pocket costs capped at $50. It is a significant price reduction aimed at proving the fiscal and medical viability of integrating metabolic health into the standard of care for the elderly. Yet participation in the BALANCE pilot is voluntary, and many payers fear that even with discounted drug prices, the sheer volume of demand could create an unsustainable financial burden on their operations.
The insurer calculus
The reluctance of private health insurers is not arbitrary. Medicare Advantage plans — the privately administered alternative to traditional fee-for-service Medicare — operate on capitated payments from the federal government. Insurers receive a fixed per-member allocation and bear the risk if actual costs exceed that amount. When a new, broadly eligible therapy enters the formulary, the financial exposure is immediate and front-loaded, while any savings from reduced hospitalizations, fewer cardiovascular events, or lower diabetes-related spending materialize only over years.
GLP-1 drugs sit at the center of this tension. The class, originally developed for type 2 diabetes, has demonstrated efficacy in reducing body weight, cardiovascular risk, and related comorbidities. But the eligible population is enormous. Obesity affects a substantial share of Medicare beneficiaries, and demand for these medications has already strained supply chains and pharmacy budgets in the commercial insurance market. Insurers participating in the pilot would be absorbing cost risk for a population that is older, sicker on average, and likely to seek treatment in large numbers. The $245 monthly price point, while far below the list price of leading GLP-1 therapies, does not eliminate that exposure — it merely compresses it.
There is also a precedent problem. Medicare Part D, the program's prescription drug benefit, has historically excluded anti-obesity medications by statute. The BALANCE pilot attempts to work around this exclusion through demonstration authority, but insurers may view the regulatory footing as uncertain. A pilot that could be rescinded, restructured, or defunded with a change in administration offers limited assurance to companies making multi-year actuarial commitments.
A policy caught between ambition and architecture
The broader challenge is architectural. Medicare was not designed to accommodate rapid integration of high-demand therapeutics into a voluntary, market-based delivery system. The Affordable Care Act and subsequent legislation expanded coverage in many directions, but the statutory prohibition on weight-loss drug coverage remained intact — a reflection of political inertia as much as policy logic. The BALANCE pilot is an attempt to demonstrate what full coverage might look like without the legislative heavy lifting of amending the Social Security Act.
That approach has strategic appeal but structural fragility. Without sufficient insurer participation, the pilot cannot generate the enrollment numbers needed to produce statistically meaningful evidence on cost-effectiveness. And without that evidence, the case for permanent legislative change weakens. The administration finds itself in a circular bind: it needs insurers to prove the concept, but insurers need proof before committing.
The pharmaceutical manufacturers, for their part, have already made pricing concessions that would have been difficult to imagine even two years ago. The question is whether discounted supply alone can overcome the demand-side hesitation of the entities responsible for bearing financial risk.
What remains unresolved is whether the federal government will sweeten the terms — through enhanced risk corridors, reinsurance mechanisms, or adjusted capitation rates — to draw insurers into the program. Absent such adjustments, the BALANCE pilot may illustrate less about the clinical promise of GLP-1 drugs for seniors and more about the structural limits of voluntary public-private partnerships in American health policy.
With reporting from STAT News.
Source · STAT News (Biotech)
